Brief: Nexalis Therapeutics Says US Policy Market Advancement Supports SRX-25 TRD Treatment
23/04/2026 02:28
April 23 (Reuters) - Nexalis Therapeutics Ltd NX1.AX: US POLICY MARKET ADVANCEMENT SUPPORTS SRX-25 TRD TREATMENT Further company coverage: NX1.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nexalis Therapeutics
See all newsBrief: Nexalis Therapeutics Says Sean Williams Has Resigned As Non-Executive Chairman
Brief: Nexalis Therapeutics Signs Funding Partnership With Point8 Capital To Replace Existing Facility
Brief: Nexalis Therapeutics Seeks Trading Halt
Brief: Nexalis Therapeutics Says US Policy Market Advancement Supports SRX-25 TRD Treatment
Australia's Nexalis Therapeutics gains most in over 6 months on trial approval